Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan in C3G or IC-MPGN
NCT03459443Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of danicopan in Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Alexion Pharmaceuticals. Started Jun 2018; status: terminated.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT03459443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459443.